SCHEMBL2504583

SCHEMBL2504583

O=C(O)[C@H]1NCCC1Cc1ccccc1F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.42
ARG1 P05089 3/20 0.40
ARG2 P78540 1/20 0.40
SLC1A2 P43004 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A3 Q01959 1/20 0.38
SIGMAR1 Q99720 2/20 0.37
ATM Q13315 1/20 0.37
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2510442 0.82 ARG1 (0.40) ARG1ARG2SLC1A2SIGMAR1ATM
SCHEMBL2509424 0.82 GAA (0.41) ARG1ARG2SLC1A2SLC6A2SLC6A3
SCHEMBL2510316 0.82 ARG1 (0.40) ARG1ARG2SLC1A2SIGMAR1CYP1A2
SCHEMBL2507865 0.82 SLC6A2 (0.41) ARG1ARG2SLC1A2SLC6A2SLC6A3
Hydrochloric Acid SCHEMBL14052835 0.81 GAA (0.40) ARG1ARG2SLC1A2SLC6A2SLC6A3
Hydrochloric Acid SCHEMBL14052941 0.81 ARG1 (0.39) ARG1ARG2SLC1A2SIGMAR1CYP1A2
Hydrochloric Acid SCHEMBL14053067 0.81 ARG1 (0.39) ARG1ARG2SLC1A2SIGMAR1ATM
Hydrochloric Acid SCHEMBL14053263 0.81 SLC6A2 (0.41) ARG1ARG2SLC1A2SLC6A2SLC6A3
Hydrochloric Acid SCHEMBL14053036 0.81 SLC6A2 (0.45) SLC6A2SLC6A3ALDH1A1KDM4E
SCHEMBL2507906 0.80 CYP2D6 (0.54) ALDH1A1CYP1A2CYP2D6MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116510024-A Composition, preparation method and application thereof 上海复东生物医药有限责任公司 2023-08-01 CN claimed
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-07-02 US disclosed
CN-113967258-B FAP-activated therapeutic agents and related uses 塔夫茨大学信托人 2024-07-02 CN disclosed
WO-2024130161-A2 NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF BIONECURE THERAPEUTICS INC (US) 2024-06-20 WO disclosed
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-03-12 US disclosed
US-20240034753-A1 THERAPEUTIC PEPTIDES COHBAR, INC. 2024-02-01 US disclosed
EP-4299134-A2 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO Bach Biosciences, LLC (US) 2024-01-03 EP disclosed
US-11753445-B2 Therapeutic peptides COHBAR, INC. (US) 2023-09-12 US disclosed
WO-2023143608-A1 COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF 上海复东生物医药有限责任公司 2023-08-03 WO disclosed
CN-116510024-A Composition, preparation method and application thereof 上海复东生物医药有限责任公司 2023-08-01 CN disclosed
CN-101466408-A Polycation-polyanion complexes, compositions, and methods of use thereof AERIS THERAPEUTICS INC (US) 2009-06-24 CN disclosed
WO-2009006473-A2 PRO-SOFT POLYPEPTIDE PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2009-01-08 WO disclosed
WO-2008128064-A2 TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS TRUSTEES OF TUFTS COLLEGE (US) 2008-10-23 WO disclosed
WO-2008119005-A1 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV TRUSTEES OF TUFTS COLLEGE (US) 2008-10-02 WO disclosed
WO-2008118848-A1 N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV TRUSTEES OF TUFTS COLLEGE (US) 2008-10-02 WO disclosed
WO-2008116053-A2 FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-09-25 WO disclosed
WO-2008116054-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2008-09-25 WO disclosed
EP-1948243-A2 POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF Aeris Therapeutics, Inc. (US) 2008-07-30 EP disclosed
WO-2007055950-A2 POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF AERIS THERAPEUTICS, INC. (US) 2007-05-18 WO disclosed
US-20070110813-A1 Polycation-polyanion complexes, compositions and methods of use thereof AERIS THERAPEUTICS, INC. (US) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 PLG 1275/4885ARG1 1689/4885ARG2 2296/4885
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 PLG 1653/4885ARG1 2867/4885ARG2 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.